Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Ping Zou, Mingxing Guo & Jingbo Hu. (2022) Evogliptin for the treatment option for type 2 diabetes: an update of the literature. Expert Review of Clinical Pharmacology 15:6, pages 747-757.
Read now
Read now
André Jacques Scheen. (2018) The safety of gliptins : updated data in 2018. Expert Opinion on Drug Safety 17:4, pages 387-405.
Read now
Read now
André J. Scheen. (2017) Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert Review of Clinical Pharmacology 10:12, pages 1303-1316.
Read now
Read now
André J. Scheen. (2017) Pharmacological management of type 2 diabetes: what’s new in 2017?. Expert Review of Clinical Pharmacology 10:12, pages 1383-1394.
Read now
Read now
Qiang Du, Yan-Jun Wang, Sheng Yang & Ping Han. (2015) Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients. Patient Preference and Adherence 9, pages 281-287.
Read now
Read now
Chin-Hsiao Tseng. (2015) Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan. Annals of Medicine 47:7, pages 561-569.
Read now
Read now
André J Scheen. (2015) Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 1005-1020.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
André J Scheen. (2015) A review of gliptins for 2014. Expert Opinion on Pharmacotherapy 16:1, pages 43-62.
Read now
Read now
Chin-Hsiao Tseng, Kuo-Yang Lee & Farn-Hsuan Tseng. (2015) An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers. Journal of Environmental Science and Health, Part C 33:1, pages 67-124.
Read now
Read now
Jocelyn de Heer & Burkhard Göke. (2014) Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety 13:11, pages 1469-1481.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Maliheh Safavi, Alireza Foroumadi & Mohammad Abdollahi. (2013) The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opinion on Drug Discovery 8:11, pages 1339-1363.
Read now
Read now
Carolyn F Deacon & Jens J Holst. (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy 14:15, pages 2047-2058.
Read now
Read now
Articles from other publishers (21)
André J. Scheen. (2021) Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism 47:6, pages 101275.
Crossref
Crossref
Anca Pantea Stoian, Alexandros Sachinidis, Roxana Adriana Stoica, Dragana Nikolic, Angelo Maria Patti & Ali A. Rizvi. (2020) The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. Metabolism 109, pages 154295.
Crossref
Crossref
Omnia Azmy Nabeh, Magdy Ishak Attallah & Nawal El‐Sayed El‐Gawhary. (2020) The pivotal relation between glucagon‐like peptides, NFκB and inflammatory bowel disease. Clinical and Experimental Pharmacology and Physiology.
Crossref
Crossref
Iku Niinomi, Keiko Hosohata, Saki Oyama, Ayaka Inada, Tomohito Wakabayashi & Kazunori Iwanaga. (2019) Pharmacovigilance Assessment of Drug-Induced Acute Pancreatitis Using a Spontaneous Reporting Database. International Journal of Toxicology 38:6, pages 487-492.
Crossref
Crossref
Mirza Muhammad Faran Ashraf Baig, Muhammad Naveed, Muhammad Abbas, Wen Chunxia, Sana Ullah, Muhammad Hasnat, Asam Shad, Muhammad Sohail, Ghulam Jilany Khan & Muhammad Tayyab Ansari. (2019) DNA scaffold nanoparticles coated with HPMC/EC for oral delivery. International Journal of Pharmaceutics 562, pages 321-332.
Crossref
Crossref
Nurhayat Ozkan Sevencan, Aysegul Ertinmaz Ozkan & Burcak Kayhan. (2018) Linagliptin-related pancreatitis in a diabetic patient with biliary calculus. Medicine 97:50, pages e13284.
Crossref
Crossref
P. Sneha & C. George Priya Doss. (2016) Gliptins in managing diabetes - Reviewing computational strategy. Life Sciences 166, pages 108-120.
Crossref
Crossref
Tzu-Yuan Wang, Cheng-Hong Hsieh, Chuan-Chuan Hung, Chia-Ling Jao, Meng-Chun Chen & Kuo-Chiang Hsu. (2015) Fish skin gelatin hydrolysates as dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 stimulators improve glycaemic control in diabetic rats: A comparison between warm- and cold-water fish. Journal of Functional Foods 19, pages 330-340.
Crossref
Crossref
Paul T. Fanta & Andrew M. Lowy. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
1761
1781
.
Chia-Ling Jao, Chuan-Chuan Hung, Yu-Shan Tung, Pei-Yi Lin, Meng-Chun Chen & Kuo-Chiang Hsu. (2015) The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes. BioMedicine 5:3.
Crossref
Crossref
Gillian M. Keating. (2015) Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 75:7, pages 777-796.
Crossref
Crossref
Saul Genuth. (2015) Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!. Diabetes Care 38:1, pages 170-175.
Crossref
Crossref
Shih-Li Huang, Chuan-Chuan Hung, Chia-Ling Jao, Yu-Shan Tung & Kuo-Chiang Hsu. (2014) Porcine skin gelatin hydrolysate as a dipeptidyl peptidase IV inhibitor improves glycemic control in streptozotocin-induced diabetic rats. Journal of Functional Foods 11, pages 235-242.
Crossref
Crossref
Kate McKeage. (2014) Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:16, pages 1927-1946.
Crossref
Crossref
Hsin-Chun Chou, Wen-Wen Chen & Fei-Yuan Hsiao. (2014) Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study. Drug Safety 37:7, pages 521-528.
Crossref
Crossref
Gillian M. Keating. (2014) Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus. Drugs 74:5, pages 587-610.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
Harold E. Lebovitz. (2013) Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects. Diabetes Technology & Therapeutics 15:11, pages 909-913.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2015) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref
Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S. Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J. Rao, Abhaya M. Dandekar & Félix M. Goñi. (2013) Dipeptidyl peptidase-IV inhibitors used in type-2 diabetes inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. F1000Research 2, pages 286.
Crossref
Crossref